This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad To Present New Molecular Data For Patients With Prostate Cancer At The American Urological Association 2013 Annual Meeting

Below is a summary of the key data being presented at the 2013 American Urological Association annual meeting.

POSTER #985: Value of Cell Cycle Progression (CCP) Score to Predict Biochemical Recurrence (BCR) and Definitive Post-Surgical Pathology

Poster Presentation, Monday, May 6, 2013

Results from this prospectively-designed clinical study show that in patients who underwent radical prostatectomy, PROLARIS (CCP) score correlated significantly with organ confined, local invasive and systemic tumor growth, and these correlations remained after adjusting for Gleason score, PSA level and clinical stage. The PROLARIS score significantly represents real clinically and biologically relevant tumor features qualifying it as a promising biomarker for active surveillance in the post-surgical decision making processes as well as pre-surgical decision making processes as demonstrated in earlier clinical studies.

Key findings from this study demonstrate that the PROLARIS test was:
  • A highly significant predictor of biochemical recurrence;  
  • Identified as a significant factor in predicting pathologic stage T3 cancer; and  
  • The best predictor for biochemical recurrence in low risk patients, whereas Gleason score was not significant.

POSTER #2242: Prognostic Utility of Cell Cycle Progression Score in Men with Prostate Cancer After Primary External Beam Radiation Therapy

Poster Presentation, Wednesday, May 8, 2013

Results from this prospectively-designed clinical study show that in patients who underwent external beam radiation therapy, the PROLARIS (CCP) score was significantly associated with survival outcome after radiation therapy and provided prognostic information beyond what was available from clinical parameters including Gleason score, PSA level and clinical stage. The PROLARIS score could be used to select high-risk men undergoing radiation treatment who may need combination therapy for their clinically localized prostate cancer.

Key findings from the study include:
  • 57 percent of study subjects from the Durham VA Medical Center were African Americans;   
  • The PROLARIS score was a significant prognostic variable (the hazard ratio for biochemical recurrence was 2.55);  
  • The PROLARIS test provides prognostic information that is not provided by standard clinical parameters; and  
  • The PROLARIS score was significantly associated with prostate cancer specific mortality.

About Prostate Cancer

According to the Centers for Disease Control and Prevention (CDC), prostate cancer is one of the most common cancers among men and is a the leading causes of cancer death. Approximately 240,000 cases of prostate cancer are diagnosed and more than 28,000 men die from the cancer annually in the United States.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 0.00%
FB $101.91 0.00%
GOOG $683.11 0.00%
TSLA $150.47 0.00%
YHOO $26.76 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs